Detection of Clonality in Hodgkin Lymphoma Following the BIOMED-2 Protocol: A Study on Paraffin-Embedded Tissue
JL Mate, G Tapia, MD Lopez, MT Fernandez-Figueras, C Sanz, A Ariza. Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Badalona, Barcelona, Spain
Background: Clonality detection plays a crucial role in the diagnosis and follow-up of lymphoproliferative conditions. PCR technique standardization by the BIOMED-2 cooperative group allows detection of clonality in up to 98% of non-Hodgkin B-cell lymphoma cases. The few Hodgkin lymphoma (HL) studies done on this subject have used varying methodological approaches and show disparate results.
Design: 47 consecutive HL cases, including 42 instances of classic HL (cHL) and 5 instances of nodular lymphocytic predominant HL (NLPHL), were studied. The number of CD30-positive cells (<10/HPF, 10-25/HPF, >25/HPF), density of accompanying CD20-positive cells (low or high), and neoplastic cell phenotype were evaluated. Clonality was assessed on paraffin-embedded tissue following the BIOMED-2 BMH4-CT98-3936 protocol for IgH and IgK, with the aid of ABI 3100 and/or heteroduplex analysis.
Results: Of the 42 cHL cases, tissue was insufficient in 7. The remaining 35 cHL cases showed IgH clonality in 6 (17.14 %) instances and IgK clonality in 9 (25.71 %) instances. No correlation was identified between the number of CD30-positive or CD20-positive cells and clonality detection. Of the 5 NLPHL cases studied, tissue was insufficient in 1 and none of the remaining 4 showed clonal rearrangement.
Conclusions: In our hands, combined study of IgH and IgK rearrangement following the BIOMED-2 protocol allows demonstration of clonality in up to 25% of cases of HL when using paraffin-embedded, nonmicrodissected tissue.
Wednesday, March 24, 2010 9:30 AM
Poster Session V # 204, Wednesday Morning